Nabriva Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBRVF research report →
Price Chart
About the company
Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration.
- CEO
- H. Michael Hogan
- IPO
- 2023
- Employees
- 39
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on NBRVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $323
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
- Gross Margin
- 19.87%
- Op Margin
- -155.57%
- Net Margin
- -160.33%
- ROE
- -201.91%
- ROIC
- -617.04%
Latest fiscal year · YoY change
- Revenue
- $35.67M+31.1%
- Gross Profit
- $7.09M-49.6%
- Op Income
- $-55,490,000
- Net Income
- $-57,185,000-15.6%
- EPS
- $-21.32+25.2%
- OCF Growth
- +38.4%
- FCF Growth
- +38.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.68
- RSI (14)
- 48
- Avg Volume
- 17
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nabriva said SIVEXTRO continued to grow, costs and cash burn improved materially, and the company is now pursuing strategic options while awaiting XENLETA CF data by year-end.· November 10, 2022
- SIVEXTRO had 16% quarter-on-quarter TRx demand growth and 16% prescription demand growth year over year, with 1,148 retail prescriptions in the quarter.
- Total revenue was $9.2 million, up 3% year over year; net sales were $8.6 million, up 10% year over year.
- Operating cash burn improved 50% versus the prior year, and SG&A fell 3% year over year as the company cut costs.
- Management said cash and cash equivalents were $14.8 million at quarter-end and runway was extended into Q1 2023.
- The company engaged Torreya Capital to explore strategic options across the portfolio, including potentially one or more brands or combinations.
Total revenue in Q3 2022 was $9.2 million, up 3% versus Q3 2021, driven primarily by SIVEXTRO net sales. Net sales were $8.6 million, up 10% year over year. SIVEXTRO prescription demand rose 16% quarter on quarter and 16% year over year, while year-to-date prescription demand was up 18%. SG&A decreased 3% versus Q3 2021, operating cash burn improved 50% versus the prior year period, and the company paid down approximately $1 million of Hercules debt. Cash and cash equivalents were $14.8 million at quarter-end, and the cash runway was extended into Q1 2023. Management did not provide formal next-quarter or full-year revenue guidance, but said top-line Phase I cystic fibrosis data for XENLETA is now expected in Q4 2022, accelerated from prior guidance of Q1 2023; lefamulin China approval remains expected in 2H 2023.
Ted Schroeder’s message was that the market undervalues the company and that the best near-term path is to preserve cash, keep growing SIVEXTRO, and evaluate strategic alternatives. He emphasized that SIVEXTRO has become a foundational revenue-generating asset, that XENLETA still has untapped upside in CAP, CF, and outside the U.S., and that CONTEPO offers another long-dated opportunity with patent exclusivity through 2038. His tone was constructive and opportunistic, repeatedly pointing to operational execution and value creation potential rather than near-term expansion spending.
Dan Dolan focused on the financial discipline measures and the resulting improvement in operating leverage. He reported Q3 revenue of $9.2 million, net sales of $8.6 million, SG&A down 3%, and operating cash burn down 50% year over year; he also noted about $1 million of Hercules debt was repaid and cash was $14.8 million at quarter-end. He said the workforce reduction and other restructuring actions would start to show more savings as the calendar turned to 2023, and that some ATM activity in the quarter raised a few million dollars, though the company was not very active with it.
Analysts focused on the 40% headcount reduction and asked when the 20% OpEx savings would show up; management said most of the savings would not be realized in Q3 or Q4 because of separation agreements, with more benefit starting in 2023. Questions also centered on the XENLETA cystic fibrosis program, where management said the upcoming readout is a PK and safety study with no efficacy endpoint, and that the next step would depend on the data and on whether a registrational program makes sense later. On strategic options, management said Torreya is evaluating all possibilities and that the company is open to one or all brands, or combinations.
The bullish case from the call is that SIVEXTRO appears to be gaining real traction, with double-digit prescription demand growth and management saying fourth quarter demand should sustain the trend. Cost cuts and better cash management materially reduced burn and extended runway into Q1 2023, giving the company time to pursue strategic alternatives and await catalysts. Management also highlighted multiple optionality points across the portfolio, including XENLETA CF data, China approval timing, and CONTEPO’s long patent life.
The key risks are the limited cash runway, a difficult capital-raising environment, and management’s own view that the stock is trading at a steep discount to cash and assets. The XENLETA CF study is only PK and safety, not efficacy, so it may not create a clear development path or commercial catalyst. SIVEXTRO’s revenue was affected by wholesaler timing, and the company is still dependent on execution and outside strategic outcomes to unlock value.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.0%
- Shares Outstanding
- 3.23M
- Float Shares
- 3.04M
Our NBRVF coverage
Recent articles, reports, and earnings notes.
No research on NBRVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBRVF report →